United States Antimony Corporation carries genuine but limited sell-side coverage. I reviewed four individual analyst price targets, each tied to a named firm and date: H.C. Wainwright (Heiko Ihle) at $9.25 (August 2026), Texas Capital Securities at $9.50 (October 2026), Alliance Global Partners (Jake Sekelsky) at $13.50 (May 2026), and B. Riley Securities at $13.00 (March 2026). The arithmetic mean of these four targets comes to roughly $11.31, which rounds to a central target of $11.30. The full range spans $9.25 to $13.50.
All four analysts rate the shares a Buy, producing a "Strong Buy" consensus with no Hold or Sell ratings. Dispersion remains meaningful, however. The two most recent targets — issued after UAMY's 2026 results deteriorated — cluster near $9.25–$9.50, while the $13.00–$13.50 figures predate the sharp decline and reflect earlier, more optimistic assumptions. H.C. Wainwright notably reduced its target to $9.25 from $11.75 in August 2026, while Texas Capital initiated coverage in October 2026 at $9.50. This downward revision pattern forms the central tension in the analyst view: bullish ratings persist, yet price objectives continue to be marked down. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The shares last traded around $3.15, near the low end of a 52-week range of roughly $2.53 to $14.05. Reaching the $11.30 central target implies a move of about 259%, which is a very large advance and would require a near-trebling of the current price. The path would have to run through several layers of prior supply, given that the stock traded at these higher levels earlier in 2026 before a prolonged selloff.
That gap reflects a changed fundamental picture. UAMY posted meaningful revenue growth in late 2025 on sharply higher antimony prices, but 2026 brought a reversal: second-quarter 2026 revenue of about $7.9 million fell roughly 25% year over year, with a negative operating income and continued net losses. Full-year 2026 EPS estimates have been revised down to roughly negative $0.07 from modestly positive figures earlier in the year. A move toward $11.30 would therefore depend less on current profitability and more on a renewed antimony price upcycle and execution of the company's expansion plans.
UAMY's strategic position is its strongest asset. It operates the Thompson Falls smelter in Montana, described as the only significant antimony smelter in the United States, making it a rare domestic source of a critical mineral used in flame retardants, batteries, and ammunition primers. China dominates global antimony supply, and its 2024 export controls elevated antimony's strategic importance. UAMY has also secured a contract with the U.S. National Defense Stockpile — including an initial order for 315,000 pounds of antimony metal ingots — underscoring its defense relevance.
Beyond antimony, management is expanding into cobalt and tungsten and has added North American mining claims, while institutional ownership has grown, with BlackRock reported to have increased its stake above 5%. A sustained rise in antimony prices, successful smelter capacity expansion, or additional government orders could each re-accelerate the growth story that analysts originally cited for their higher targets.
The principal obstacle is that the company is currently shrinking and unprofitable, even as analysts maintain Buy ratings. Declining revenue, negative operating income, and downward EPS revisions point to operational and pricing headwinds. The stock also trades at a premium valuation on a price-to-sales basis versus materials peers, leaving little cushion if sentiment cools further. Antimony prices are volatile and heavily tied to Chinese export policy; any normalization or relaxation of those restrictions could compress the price of UAMY's core product.
Recurring equity raises and shareholder dilution have historically weighed on the shares, and the company's modest market capitalization of roughly $450–570 million makes it prone to outsized swings. The wide spread between the older $13.00–$13.50 targets and the newer $9.25–$9.50 targets is itself a warning that the analysts' models remain in flux.
The stock's decline from a 2026 high near $14 to the low $3 range leaves clear structural markers. The 52-week low near $2.53 acts as the primary support level, with the $2.64–$3.00 zone representing the next major floor. On the upside, resistance is layered: the recent trading band of roughly $3.20–$3.40 is the first hurdle, followed by the $4–$5 area and then far more distant levels associated with the earlier 2026 breakdown. The $10 psychological level sits just below the central target and would be a significant milestone. In short, the current price sits near long-term support, but the distance to the $11.30 objective is technically extreme.
Analyst price targets typically reflect a research horizon of about 12 months, though the four targets here were published across several months and should not be read as a synchronized forecast. Investors should monitor antimony spot prices and any change in Chinese export policy, quarterly revenue and operating income trends, and progress on the Thompson Falls expansion and defense-contract deliveries. Upcoming catalysts include UAMY's next earnings report and a scheduled B. Riley investor meeting in mid-November 2026. Further analyst target revisions — particularly whether the older $13.00–$13.50 figures are lowered — will be a key signal of conviction.
Can UAMY reach $11.30? The question rests on an analyst-derived central target that is the arithmetic mean of four published price objectives, and it sits roughly 259% above the current price — a very large hurdle that would require a near-trebling of the stock. The bullish case is anchored in UAMY's unique domestic smelter, its defense-stockpile contract, and its exposure to a critical mineral dominated by China. The bearish case is anchored in declining revenue, ongoing losses, and a stock that has already given back most of its 2026 gains. The wide $9.25–$13.50 target range, and the fact that the newest targets are the lowest, suggests analysts remain constructive but are steadily tempering their expectations. Whether the stock can close that gap depends on antimony prices, execution, and government demand — none of which is guaranteed. The target is a reference point, not a forecast.
Investors tracking volatile, event-driven names like UAMY can supplement traditional research with AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a stock that has swung from $14 to $3 within a year, having an automated system that flags shifting momentum and risk can help traders discover opportunities, monitor positions, and spot changing trends more efficiently.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UAMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 36 cases where UAMY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where UAMY's RSI Indicator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 64 cases where UAMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for UAMY just turned positive on October 22, 2026. Looking at past instances where UAMY's MACD turned positive, the stock continued to rise in 40 of 55 cases over the following month. The odds of a continued upward trend are 73%.
Following a +33.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where UAMY advanced for three days, in 203 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UAMY as a result. In 79 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UAMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for UAMY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. UAMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UAMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.332) is normal, around the industry mean (6.813). P/E Ratio (-21.692) is within average values for comparable stocks, (-0.701). UAMY's Projected Growth (PEG Ratio) (9.440) is very high in comparison to the industry average of (1.026). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (17.241) is also within normal values, averaging (283.864).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of antimony products
Industry OtherMetalsMinerals